Endocrinology and Nutrition Department, Hospital Universitario Son Llàtzer. Health Research Institute of the Balearic Islands (IdISBa) .Ctra Manacor km 4, 07198 Palma de Mallorca, Baleares, Spain; Clínica Rotger (Grupo Quirón). Via Roma,3. 07012 Palma de Mallorca, Baleares Spain.
Endocrinology and Nutrition Department, Hospital Universitario Son Llàtzer. Health Research Institute of the Balearic Islands (IdISBa) .Ctra Manacor km 4, 07198 Palma de Mallorca, Baleares, Spain.
Physiol Behav. 2022 Dec 1;257:113967. doi: 10.1016/j.physbeh.2022.113967. Epub 2022 Sep 24.
Emotional eating (EE) and other abnormal eating patterns are highly prevalent among people living with obesity (PWO). In this sense, semaglutide, by acting on areas of the brain involved in the reward system and emotion regulation, could have the potential to ameliorate these eating patterns.
69 PWO attending an obesity clinic were evaluated baseline and after 3 months since the beginning of semaglutide. To rule out abnormal EE, the Emotional Eating Questionnaire was administered, and a structured interview was conducted.
69 PWO (82.6%♀, 43.7 ± 1years, and 34.3 ± 6 kg/m) were included. After 3 months of semaglutide, there was a significant reduction in weight (96.1 ± 20.9 vs 91.3 ± 19.7 kg; p < 0.001) and BMI (34.3 ± 6 vs 32.4 ± 5.6 kg/m; p < 0.0001). The proportion of patients with EE (72.5% vs 11.5%; p < 0.001), external eating (27.5% vs 10.1%; p < 0.001) cravings (49.3% vs 21.7%; p < 0.001) and savory cravings (53.6% vs 14.5%; p < 0.001) was significantly reduced after 3 months of semaglutide. Also, the proportion of PWO with regular exercise was increased (15.9% vs 39.1%; p < 0.001). However, Logistic regression analysis showed that only sweet cravings at baseline were the only factor associated, although not significant, with a poorer weight loss (p = 0.05).
Semaglutide is an effective weight-loss treatment in PWO at short term. Moreover, semaglutide was highly effective in ameliorating EE and other abnormal eating patterns that exert a negative influence on weight.
情绪性进食（EE）和其他异常进食模式在肥胖患者（PWO）中非常普遍。在这种情况下，司美格鲁肽通过作用于大脑中参与奖励系统和情绪调节的区域，有可能改善这些进食模式。
评估了 69 名参加肥胖诊所的 PWO 患者的基线数据，并在开始司美格鲁肽治疗后 3 个月进行了评估。为了排除异常 EE，我们使用了情绪性进食问卷，并进行了结构化访谈。
共纳入 69 名 PWO（82.6%♀，43.7±1 岁，34.3±6kg/m）。在接受司美格鲁肽治疗 3 个月后，体重（96.1±20.9 与 91.3±19.7kg；p<0.001）和 BMI（34.3±6 与 32.4±5.6kg/m；p<0.0001）均显著下降。EE（72.5% 与 11.5%；p<0.001）、外食（27.5% 与 10.1%；p<0.001）、渴望（49.3% 与 21.7%；p<0.001）和咸味渴望（53.6% 与 14.5%；p<0.001）的患者比例在接受司美格鲁肽治疗 3 个月后显著降低。此外，定期运动的 PWO 比例增加（15.9% 与 39.1%；p<0.001）。然而，Logistic 回归分析显示，只有基线时的甜食渴望是与减重效果较差相关的唯一因素（尽管无统计学意义，p=0.05）。
司美格鲁肽是一种短期治疗肥胖患者的有效减重治疗方法。此外，司美格鲁肽在改善 EE 和其他对体重有负面影响的异常进食模式方面非常有效。
